- Home
- KTF vs GNLX Comparison
KTF vs GNLX Comparison
Compare KTF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- GNLX
- Stock Information
- Founded
- KTF 1988
- GNLX 2001
- Country
- KTF United States
- GNLX United States
- Employees
- KTF N/A
- GNLX N/A
- Industry
- KTF Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- GNLX Health Care
- Exchange
- KTF Nasdaq
- GNLX Nasdaq
- Market Cap
- KTF 349.0M
- GNLX 112.8M
- IPO Year
- KTF N/A
- GNLX 2023
- Fundamental
- Price
- KTF $8.82
- GNLX $3.41
- Analyst Decision
- KTF
- GNLX Strong Buy
- Analyst Count
- KTF 0
- GNLX 4
- Target Price
- KTF N/A
- GNLX $17.75
- AVG Volume (30 Days)
- KTF 103.3K
- GNLX 142.7K
- Earning Date
- KTF 01-01-0001
- GNLX 08-13-2025
- Dividend Yield
- KTF 3.54%
- GNLX N/A
- EPS Growth
- KTF N/A
- GNLX N/A
- EPS
- KTF 0.39
- GNLX N/A
- Revenue
- KTF N/A
- GNLX N/A
- Revenue This Year
- KTF N/A
- GNLX N/A
- Revenue Next Year
- KTF N/A
- GNLX N/A
- P/E Ratio
- KTF $23.10
- GNLX N/A
- Revenue Growth
- KTF N/A
- GNLX N/A
- 52 Week Low
- KTF $7.40
- GNLX $1.60
- 52 Week High
- KTF $9.12
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- KTF 44.61
- GNLX 64.69
- Support Level
- KTF $8.71
- GNLX $2.80
- Resistance Level
- KTF $8.93
- GNLX $3.61
- Average True Range (ATR)
- KTF 0.06
- GNLX 0.22
- MACD
- KTF 0.01
- GNLX 0.04
- Stochastic Oscillator
- KTF 57.89
- GNLX 76.74
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.